FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2904486886> ?p ?o ?g. }

• W2904486886 abstract "The aim of this study was to assess whether minimal residual disease (MRD) at the end of induction front-line treatment can serve as a surrogate endpoint for event-free survival (EFS) in childhood B-lineage acute lymphoblastic leukemia.The analysis was based on individual data of 4830 patients from two large phase III trials that asked a randomized question on the effect of different corticosteroids (dexamethasone vs prednisone) during induction chemotherapy on EFS. The association between MRD classified in three ordered categories [negative = 0, low positive = (>0 and <5 × 10-4), and positive = (≥5 × 10-4)] and EFS at the individual and trial levels was evaluated with the meta-analytic approach based on the Plackett copula model. Centers within trial were grouped according to geographical area, and a total of 28 units were identified for the analysis.MRD at the end of induction was a poor surrogate for treatment effect on EFS at the trial level, with Rtrial2 = 0.09 (95% confidence interval [CI] = 0.00 to 0.29), whereas at the individual level it was strongly associated with EFS, with an odds ratio of 3.90 (95% CI = 3.35 to 4.44) of failure for patients with higher compared with lower MRD levels. Additional sensitivity and relevant subgroup analyses confirmed these findings at both trial- and patient-level association.Although MRD is a robust biomarker highly predictive of outcome for individual patients, clinicians and regulatory bodies should be cautious in using early MRD response in the context of complex multiagent acute lymphoblastic leukemia therapy as an early surrogate endpoint to predict the effect of a randomized treatment intervention on long-term EFS." @default.
• W2904486886 created "2018-12-22" @default.
• W2904486886 creator A5000288435 @default.
• W2904486886 creator A5011027150 @default.
• W2904486886 creator A5013754928 @default.
• W2904486886 creator A5015761988 @default.
• W2904486886 creator A5020812442 @default.
• W2904486886 creator A5022541563 @default.
• W2904486886 creator A5023214494 @default.
• W2904486886 creator A5023918175 @default.
• W2904486886 creator A5036614366 @default.
• W2904486886 creator A5051520180 @default.
• W2904486886 creator A5051981929 @default.
• W2904486886 creator A5056916024 @default.
• W2904486886 creator A5067719280 @default.
• W2904486886 creator A5076365826 @default.
• W2904486886 creator A5079852624 @default.
• W2904486886 creator A5080485119 @default.
• W2904486886 creator A5083575870 @default.
• W2904486886 creator A5085010022 @default.
• W2904486886 creator A5090678844 @default.
• W2904486886 date "2018-10-01" @default.
• W2904486886 modified "2023-10-17" @default.
• W2904486886 title "Validation of Minimal Residual Disease as Surrogate Endpoint for Event-Free Survival in Childhood Acute Lymphoblastic Leukemia" @default.
• W2904486886 cites W1558155053 @default.
• W2904486886 cites W1976767488 @default.
• W2904486886 cites W2001862791 @default.
• W2904486886 cites W2009079013 @default.
• W2904486886 cites W2039149330 @default.
• W2904486886 cites W2039642633 @default.
• W2904486886 cites W2075139424 @default.
• W2904486886 cites W2113092779 @default.
• W2904486886 cites W2119685895 @default.
• W2904486886 cites W2132827894 @default.
• W2904486886 cites W2148631711 @default.
• W2904486886 cites W2311406774 @default.
• W2904486886 cites W2342769258 @default.
• W2904486886 cites W2409736194 @default.
• W2904486886 cites W2518827451 @default.
• W2904486886 cites W2561188085 @default.
• W2904486886 cites W2566066691 @default.
• W2904486886 cites W2587199293 @default.
• W2904486886 cites W2612859570 @default.
• W2904486886 cites W2613210669 @default.
• W2904486886 doi "https://doi.org/10.1093/jncics/pky069" @default.
• W2904486886 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6649800" @default.
• W2904486886 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31360884" @default.
• W2904486886 hasPublicationYear "2018" @default.
• W2904486886 type Work @default.
• W2904486886 sameAs 2904486886 @default.
• W2904486886 citedByCount "10" @default.
• W2904486886 countsByYear W29044868862021 @default.
• W2904486886 countsByYear W29044868862022 @default.
• W2904486886 countsByYear W29044868862023 @default.
• W2904486886 crossrefType "journal-article" @default.
• W2904486886 hasAuthorship W2904486886A5000288435 @default.
• W2904486886 hasAuthorship W2904486886A5011027150 @default.
• W2904486886 hasAuthorship W2904486886A5013754928 @default.
• W2904486886 hasAuthorship W2904486886A5015761988 @default.
• W2904486886 hasAuthorship W2904486886A5020812442 @default.
• W2904486886 hasAuthorship W2904486886A5022541563 @default.
• W2904486886 hasAuthorship W2904486886A5023214494 @default.
• W2904486886 hasAuthorship W2904486886A5023918175 @default.
• W2904486886 hasAuthorship W2904486886A5036614366 @default.
• W2904486886 hasAuthorship W2904486886A5051520180 @default.
• W2904486886 hasAuthorship W2904486886A5051981929 @default.
• W2904486886 hasAuthorship W2904486886A5056916024 @default.
• W2904486886 hasAuthorship W2904486886A5067719280 @default.
• W2904486886 hasAuthorship W2904486886A5076365826 @default.
• W2904486886 hasAuthorship W2904486886A5079852624 @default.
• W2904486886 hasAuthorship W2904486886A5080485119 @default.
• W2904486886 hasAuthorship W2904486886A5083575870 @default.
• W2904486886 hasAuthorship W2904486886A5085010022 @default.
• W2904486886 hasAuthorship W2904486886A5090678844 @default.
• W2904486886 hasBestOaLocation W29044868861 @default.
• W2904486886 hasConcept C126322002 @default.
• W2904486886 hasConcept C141341695 @default.
• W2904486886 hasConcept C143998085 @default.
• W2904486886 hasConcept C156957248 @default.
• W2904486886 hasConcept C168563851 @default.
• W2904486886 hasConcept C203092338 @default.
• W2904486886 hasConcept C204243189 @default.
• W2904486886 hasConcept C2778461978 @default.
• W2904486886 hasConcept C2778720950 @default.
• W2904486886 hasConcept C2779823535 @default.
• W2904486886 hasConcept C44249647 @default.
• W2904486886 hasConcept C71924100 @default.
• W2904486886 hasConceptScore W2904486886C126322002 @default.
• W2904486886 hasConceptScore W2904486886C141341695 @default.
• W2904486886 hasConceptScore W2904486886C143998085 @default.
• W2904486886 hasConceptScore W2904486886C156957248 @default.
• W2904486886 hasConceptScore W2904486886C168563851 @default.
• W2904486886 hasConceptScore W2904486886C203092338 @default.
• W2904486886 hasConceptScore W2904486886C204243189 @default.
• W2904486886 hasConceptScore W2904486886C2778461978 @default.
• W2904486886 hasConceptScore W2904486886C2778720950 @default.
• W2904486886 hasConceptScore W2904486886C2779823535 @default.
• W2904486886 hasConceptScore W2904486886C44249647 @default.
• W2904486886 hasConceptScore W2904486886C71924100 @default.
• W2904486886 hasIssue "4" @default.

• next